Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

More on Sanofi, Sanofi, etc. Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January Sanofi: Diverse Drug Portfolio And Future Pipeline, 4% Dividend Yield Looks Attractive ...

including a series of drugs targeting BCMA. Sarclisa is one of two late-stage programmes that Sanofi is hoping will continue a renaissance for its cancer business along with Libtayo (cemiplimab ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s MHLW for use in conjunction with VRd to treat newly diagnosed ...

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

Sanofi & Teva's IBD drug duvakitug shows promise in Phase 2b with €1B sales potential by 2032, faces competition from Roivant ...

Paris: Sanofi has announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in ...

Sanofi Oncology global head Olivier Nataf stated ... Sarclisa's non-proprietary name in the US is isatuximab-irfc, following US Food and Drug Administration guidance for the industry on ...